Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13286271 | 0.85 | PRKCA (0.38) | ALDH1A1LMNASMN1; SMN2RAB9ACCR3 | |
| SCHEMBL771703 | 0.83 | CNR2 (0.41) | ALDH1A1LMNASMN1; SMN2RAB9APTGDR2 | |
| SCHEMBL792724 | 0.80 | CNR2 (0.37) | LMNASMN1; SMN2TP53RAB9APTGDR2 | |
| SCHEMBL792898 | 0.78 | TP53 (0.39) | ALDH1A1TP53RAB9APTGDR2CNR2 | |
| SCHEMBL792857 | 0.78 | JAK2 (0.36) | LMNASMN1; SMN2TP53SLC5A2RAB9A | |
| SCHEMBL792858 | 0.75 | KMT2A (0.39) | LMNARAB9AKMT2A | |
| SCHEMBL792659 | 0.74 | L3MBTL1 (0.47) | ALDH1A1LMNASMN1; SMN2TP53KMT2A | |
| SCHEMBL792427 | 0.73 | CNR2 (0.41) | ALDH1A1LMNATP53RAB9APTGDR2 | |
| SCHEMBL13006921 | 0.73 | CNR1 (0.33) | RAB9ACNR2NPC1 | |
| SCHEMBL792856 | 0.72 | CNR2 (0.36) | ALDH1A1TP53PTGDR2CNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885LMNA 4323/4885SMN1; SMN2 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.